Mycophenolate mofetil therapy for pediatric bullous pemphigoid.

Abstract

Bullous pemphigoid (BP) is a common autoimmune blistering disease in the adult population, but extremely rare in the pediatric population. Childhood BP usually has a favorable prognosis and responds well to topical and oral steroids. However, for patients that do not respond to corticosteroids, therapeutic alternatives are scarce. We report a case of a toddler with recalcitrant BP who was successfully treated with mycophenolate mofetil (MMF).

• Authors: Lucia Seminario-Vidal, Naveed Sami, Jonathan Miller, Amy Theos
• Journal: Dermatology online journal (Dermatol Online J) Vol. 21 Issue 8 (Aug 15 2015) ISSN: 1087-2108 [Electronic] United States
• PMID: 26437160 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Immunosuppressive Agents
• Clindamycin
• Dapsone
• Mycophenolic Acid
• Prednisone

Topics

• Anti-Bacterial Agents (therapeutic use)
• Clindamycin (therapeutic use)
• Dapsone (therapeutic use)
• Diagnosis, Differential
• Drug Resistance
• Humans
• Immunosuppressive Agents (pharmacology, therapeutic use)
• Infant
• Lymphocyte Subsets (drug effects)
• Male
• Mycophenolic Acid (analogs & derivatives, pharmacology, therapeutic use)
• Pemphigoid, Bullous (diagnosis, drug therapy)
• Prednisone (therapeutic use)
• Pruritus (drug therapy)
• Remission Induction
• Skin Diseases, Vesiculobullous (diagnosis)
• Staphylococcal Skin Infections (drug therapy, etiology)
• Superinfection (drug therapy, etiology)
• Urticaria (drug therapy)